Impact of initial chemotherapy regimen on outcomes for patients with double- expressor lymphoma: A multi- center analysis
dc.contributor.author | D’angelo, Christopher R. | |
dc.contributor.author | Hanel, Walter | |
dc.contributor.author | Chen, Yi | |
dc.contributor.author | Yu, Menggang | |
dc.contributor.author | Yang, David | |
dc.contributor.author | Guo, Ling | |
dc.contributor.author | Karmali, Reem | |
dc.contributor.author | Burkart, Madelyn | |
dc.contributor.author | Ciccosanti, Colleen | |
dc.contributor.author | David, Kevin | |
dc.contributor.author | Risch, Zachary | |
dc.contributor.author | Murga‐Zamalloa, Carlos | |
dc.contributor.author | Devata, Sumana | |
dc.contributor.author | Wilcox, Ryan | |
dc.contributor.author | Savani, Malvi | |
dc.contributor.author | Courville, Elizabeth L. | |
dc.contributor.author | Bachanova, Veronika | |
dc.contributor.author | Rabinovich, Emma | |
dc.contributor.author | Peace, David | |
dc.contributor.author | Osman, Fauzia | |
dc.contributor.author | Epperla, Narendranath | |
dc.contributor.author | Kenkre, Vaishalee P. | |
dc.date.accessioned | 2021-11-02T00:45:16Z | |
dc.date.available | 2022-11-01 20:45:15 | en |
dc.date.available | 2021-11-02T00:45:16Z | |
dc.date.issued | 2021-10 | |
dc.identifier.citation | D’angelo, Christopher R. ; Hanel, Walter; Chen, Yi; Yu, Menggang; Yang, David; Guo, Ling; Karmali, Reem; Burkart, Madelyn; Ciccosanti, Colleen; David, Kevin; Risch, Zachary; Murga‐Zamalloa, Carlos ; Devata, Sumana; Wilcox, Ryan; Savani, Malvi; Courville, Elizabeth L.; Bachanova, Veronika; Rabinovich, Emma; Peace, David; Osman, Fauzia; Epperla, Narendranath; Kenkre, Vaishalee P. (2021). "Impact of initial chemotherapy regimen on outcomes for patients with double- expressor lymphoma: A multi- center analysis." Hematological Oncology 39(4): 473-482. | |
dc.identifier.issn | 0278-0232 | |
dc.identifier.issn | 1099-1069 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/170812 | |
dc.description.abstract | Diffuse large B- cell lymphoma featuring overexpression of MYC and B- Cell Lymphoma 2 (double expressor lymphoma, DEL) is associated with poor outcomes. Existing evidence suggesting improved outcomes for DEL with the use of more intensive regimens than R- CHOP is restricted to younger patients and based on limited evidence from low patient numbers. We retrospectively evaluated the impact of intensive frontline regimens versus R- CHOP in a multicenter analysis across 7 academic medical centers in the United States. We collected 90 cases of DEL, 46 out of 90 patients (51%) received R- CHOP and 44/90 (49%) received an intensive regimen, which was predominantly DA- EPOCH- R. Treatment cohorts were evenly balanced for demographics and disease characteristics, though the intensive group had a higher lactate dehydrogenase (LDH, 326 vs. 230 U/L p = 0.06) and presence of B- symptoms (50% vs. 22%, p = 0.01) compared to the R- CHOP cohort. There was no difference in PFS (median 53 vs. 38 months, p = 0.49) or overall survival (67 vs. not reached months, p = 0.14) between the R- CHOP and intensive therapy cohorts, respectively. On multivariate analysis, intensive therapy was associated with a hazard ratio of 2.35 (95% CI 0.74- 7.41), though this was not statistically significant. Additionally, a subgroup analysis of intermediate high- risk lymphoma defined by IPI - ¥3 did not identify a difference in survival outcomes between regimens. We conclude that in our multi- center cohort there is no evidence supporting the use of intensive regimens over R- CHOP, suggesting that R- CHOP remains the standard of care for treating DEL. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | double expressor lymphoma | |
dc.subject.other | initial therapy | |
dc.subject.other | retrospective clinical analysis | |
dc.title | Impact of initial chemotherapy regimen on outcomes for patients with double- expressor lymphoma: A multi- center analysis | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Otolaryngology | |
dc.subject.hlbsecondlevel | Neurosciences | |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Ophthalmology | |
dc.subject.hlbsecondlevel | Public Health | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/170812/1/hon2902.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/170812/2/hon2902_am.pdf | |
dc.identifier.doi | 10.1002/hon.2902 | |
dc.identifier.source | Hematological Oncology | |
dc.identifier.citedreference | Shah NN, Szabo A, Huntington SF, et al. R- CHOP versus dose- adjusted R- EPOCH in frontline management of primary mediastinal B- cell lymphoma: a multi- centre analysis. Br J Haematol. 2018; 180 ( 4 ): 534 - 544. | |
dc.identifier.citedreference | Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016; 127 ( 18 ): 2182 - 2188. | |
dc.identifier.citedreference | Maurer MJ, Ghesquieres H, Jais JP, et al. Event- free survival at 24 months is a robust end point for disease- related outcome in diffuse large B- cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32 ( 10 ): 1066 - 1073. | |
dc.identifier.citedreference | Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non- Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32 ( 27 ): 3059 - 3067. | |
dc.identifier.citedreference | Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B- cell lymphoma. N Engl J Med. 2018; 378 ( 15 ): 1396 - 1407. | |
dc.identifier.citedreference | Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B- cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103 ( 1 ): 275 - 282. | |
dc.identifier.citedreference | Rosenthal A, Younes A. High grade B- cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2017; 31 ( 2 ): 37 - 42. | |
dc.identifier.citedreference | Pedersen MO, Gang AO, Brown P, et al. Real world data on young patients with high- risk diffuse large B- cell lymphoma treated with R- CHOP or R- CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. PLoS One. 2017; 12 ( 10 ): e0186983. | |
dc.identifier.citedreference | Takahashi H, Miura K, Nakagawa M, et al. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B- cell lymphoma treated with dose- intensified immunochemotherapy. Leuk Lymphoma. 2016; 57 ( 12 ): 2784 - 2790. | |
dc.identifier.citedreference | Dodero A, Guidetti A, Tucci A, et al. Dose- adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B- cell lymphoma. Leukemia. 2019; 33 ( 4 ): 1047 - 1051. | |
dc.identifier.citedreference | Bartlett NL, Wilson WH, Jung SH, et al. Dose- adjusted EPOCH- R compared with R- CHOP as frontline therapy for diffuse large B- cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019; 37 ( 21 ): 1790 - 1799. | |
dc.identifier.citedreference | Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127 ( 20 ): 2375 - 2390. | |
dc.identifier.citedreference | Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B- cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30 ( 28 ): 3452 - 3459. | |
dc.identifier.citedreference | Hu S, Xu- Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B- cell subtype of diffuse large B- cell lymphoma and demonstrates high- risk gene expression signatures: a report from the International DLBCL Rituximab- CHOP Consortium Program. Blood. 2013; 121 ( 20 ): 4021 - 4031; quiz 250. | |
dc.identifier.citedreference | Staiger AM, Ziepert M, Horn H, et al. Clinical impact of the cell- of- origin classification and the MYC/BCL2 dual expresser status in diffuse large B- cell lymphoma treated within prospective clinical trials of the German high- grade non- Hodgkin’s lymphoma study group. J Clin Oncol. 2017; 35 ( 22 ): 2515 - 2526. | |
dc.identifier.citedreference | Green TM, Young KH, Visco C, et al. Immunohistochemical double- hit score is a strong predictor of outcome in patients with diffuse large B- cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30 ( 28 ): 3460 - 3467. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.